Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CFO Dominic Piscitelli sold 77,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer owned 69,828 shares of the company’s stock, valued at $955,945.32. This trade represents a 52.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oric Pharmaceuticals Price Performance
Shares of ORIC stock opened at $13.24 on Friday. Oric Pharmaceuticals, Inc. has a 1-year low of $7.23 and a 1-year high of $14.93. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -9.81 and a beta of 1.02. The stock has a 50 day simple moving average of $11.85 and a 200-day simple moving average of $10.73.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Analysts anticipate that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Oric Pharmaceuticals
Hedge Funds Weigh In On Oric Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. Defilade Capital Management L.P. acquired a new position in shares of Oric Pharmaceuticals during the 1st quarter valued at about $10,680,000. Siren L.L.C. raised its stake in Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after purchasing an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Oric Pharmaceuticals by 19.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after purchasing an additional 244,060 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at approximately $4,332,000. Finally, Bank of America Corp DE increased its holdings in shares of Oric Pharmaceuticals by 105.5% during the 1st quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock worth $13,217,000 after buying an additional 535,649 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.
About Oric Pharmaceuticals
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Read More
- Five stocks we like better than Oric Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
